The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Building Disease-Specific Drug-Protein Connectivity Maps from Molecular Interaction Networks and PubMed Abstracts
Open accessAbstract
The recently proposed concept of molecular connectivity maps enables researchers to integrate experimental measurements of genes, proteins, metabolites, and drug compounds under similar biological conditions. The study of these maps provides opportunities for future toxicogenomics and drug discovery applications. We developed a computational framework to build disease-specific drug-protein connectivity maps. We integrated gene/protein and drug connectivity information based on protein interaction networks and literature mining, without requiring gene expression profile information derived from drug perturbation experiments on disease samples. We described the development and application of this computational framework using Alzheimer's Disease (AD) as a primary example in three steps. First, molecular interaction networks were incorporated to reduce bias and improve relevance of AD seed proteins. Second, PubMed abstracts were used to retrieve enriched drug terms that are indirectly associated with AD through molecular mechanistic studies. Third and lastly, a comprehensive AD connectivity map was created by relating enriched drugs and related proteins in literature. We showed that this molecular connectivity map development approach outperformed both curated drug target databases and conventional information retrieval systems. Our initial explorations of the AD connectivity map yielded a new hypothesis that diltiazem and quinidine may be investigated as candidate drugs for AD treatment. Molecular connectivity maps derived computationally can help study molecular signature differences between different classes of drugs in specific disease contexts. To achieve overall good data coverage and quality, a series of statistical methods have been developed to overcome high levels of data noise in biological networks and literature mining results. Further development of computational molecular connectivity maps to cover major disease areas will likely set up a new model for drug development, in which therapeutic/toxicological profiles of candidate drugs can be checked computationally before costly clinical trials begin.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482 · cited 1×
“We used a standard multiple testing correction method [54] in microarray analysis to convert p-values from the t-test to calculate a drug’s false discovery rate (FDR).”
MethodSystems biology: a brief overview
Kitano, H. (2002) · Science · doi:10.1126/science.1069492 · Cited by 4,265
Protein biomarker discovery and validation: the long and uncertain path to clinical utility
Rifai, N., Gillette, M. A., & Carr, S. A. (2006) · Nature Biotechnology · doi:10.1038/nbt1235 · Cited by 1,867
The Connectivity Map: A new tool for biomedical research
Lamb, J. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2044 · Cited by 945 · cited 1×
“recently established a systematic approach to build connectivity maps using gene-expression profile information as the common vocabulary that connects small molecules, genes, and diseases [5].”
BackgroundForette, F. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.18.2046 · Cited by 898
Apolipoprotein E Polymorphism and Cardiovascular Disease: A HuGE Review
Eichner, J. E. (2002) · American Journal of Epidemiology · doi:10.1093/aje/155.6.487 · Cited by 796
The prolyl isomerase Pin1 restores the function of Alzheimer-associated phosphorylated tau protein
Lu, P.-J., Wulf, G., Zhou, X. Z., Davies, P., & Lu, K. P. (1999) · Nature · doi:10.1038/21650 · Cited by 721
Apolipoprotein E Inhibits Platelet Aggregation through the L-Arginine:Nitric Oxide Pathway
Riddell, D. R., Graham, A., & Owen, J. S. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.1.89 · Cited by 209 · cited 1×
“1-Methyl-3-isobutylxanthine (IBMX)’’, where IBMX treatment increased cAMP levels and diminished cGMP levels in the absence of apoE complex [35].”
BackgroundIntegrating physical and genetic maps: from genomes to interaction networks
Beyer, A., Bandyopadhyay, S., & Ideker, T. (2007) · Nature Reviews Genetics · doi:10.1038/nrg2144 · Cited by 207 · cited 1×
“Here, the concept of studying ‘‘inter-class’’ molecular associations is quite different from that of ‘‘intra-class’’ molecular associations such as gene-gene interactions, drug-drug interactions, or protein-protein interactions [3].”
Background
Cited by
Structure and dynamics of molecular networks: A novel paradigm of drug discovery
Csermely, P., Korcsmáros, T., Kiss, H. J. M., London, G., & Nussinov, R. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.01.016 · Cited by 892
PREDICT: a method for inferring novel drug indications with application to personalized medicine
Gottlieb, A., Stein, G. Y., Ruppin, E., & Sharan, R. (2011) · Molecular Systems Biology · doi:10.1038/msb.2011.26 · Cited by 881
Discovery of drug mode of action and drug repositioning from transcriptional responses
Iorio, F., Bosotti, R., Scacheri, E., Belcastro, V., Mithbaokar, P., Ferriero, R., Murino, L., Tagliaferri, R., Brunetti-Pierri, N., Isacchi, A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1000138107 · Cited by 816
Zitnik, M., Nguyen, F., Wang, B., Leskovec, J., Goldenberg, A., & Hoffman, M. M. (2019) · Information Fusion · doi:10.1016/j.inffus.2018.09.012 · Cited by 675
Review of Drug Repositioning Approaches and Resources
Xue, H., Li, J., Xie, H., & Wang, Y. (2018) · International Journal of Biological Sciences · doi:10.7150/ijbs.24612 · Cited by 614
Self-citationShaping the interaction landscape of bioactive molecules
Gfeller, D., Michielin, O., & Zoete, V. (2013) · Bioinformatics · doi:10.1093/bioinformatics/btt540 · Cited by 501
Machine learning approaches and databases for prediction of drug–target interaction: a survey paper
Bagherian, M., Sabeti, E., Wang, K., Sartor, M. A., Nikolovska-Coleska, Z., & Najarian, K. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbz157 · Cited by 429
Neighborhood Regularized Logistic Matrix Factorization for Drug-Target Interaction Prediction
Liu, Y., Wu, M., Miao, C., Zhao, P., & Li, X.-L. (2016) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1004760 · Cited by 391
Jarada, T. N., Rokne, J. G., & Alhajj, R. (2020) · Journal of Cheminformatics · doi:10.1186/s13321-020-00450-7 · Cited by 384
Elucidating Compound Mechanism of Action by Network Perturbation Analysis
Woo, J. H., Shimoni, Y., Yang, W. S., Subramaniam, P., Iyer, A., Nicoletti, P., Rodríguez Martínez, M., López, G., Mattioli, M., Realubit, R., et al. (2015) · Cell · doi:10.1016/j.cell.2015.05.056 · Cited by 351
Drug repositioning by integrating target information through a heterogeneous network model
Wang, W., Yang, S., Zhang, X., & Li, J. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu403 · Cited by 335
Self-citationInformation retrieval and text mining technologies for chemistry
Krallinger, M., Rabal, O., Lourenço, A., Oyarzabal, J., & Valencia, A. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00851 · Cited by 281
Advancing Alzheimer’s research: a review of big data promises
Zhang, R., Simon, G., & Yu, F. (2017) · International Journal of Medical Informatics · doi:10.1016/j.ijmedinf.2017.07.002 · Cited by 77
Douglass, E. F., Allaway, R. J., Szalai, B., Wang, W., Tian, T., Fernández-Torras, A., Realubit, R., Karan, C., Zheng, S., Pessia, A., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100492 · Cited by 68
Mapping of molecular pathways, biomarkers and drug targets for diabetic nephropathy
Fechete, R., Heinzel, A., Perco, P., Mönks, K., Söllner, J., Stelzer, G., Eder, S., Lancet, D., Oberbauer, R., Mayer, G., et al. (2011) · PROTEOMICS – Clinical Applications · doi:10.1002/prca.201000136 · Cited by 45
“Furthermore, concepts for building disease-specific drug-protein connectivity maps have been introduced [37], altogether aimed at building relations between molecular feature space, clinical data space, and associated markers, drug targets and associated drugs.”
BackgroundGeerts, H., Hofmann‐Apitius, M., Anastasio, T. J., & Initiative, B. H. M. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2017.08.011 · Cited by 20
A drug repositioning algorithm based on a deep autoencoder and adaptive fusion
Chen, P., Bao, T., Yu, X., & Liu, Z. (2021) · BMC Bioinformatics · doi:10.1186/s12859-021-04406-y · Cited by 8
Metadata
- Authors
- Li, J., Zhu, X., & Chen, J. Y.
- Venue
- PLoS Computational Biology
- Publisher
- Public Library of Science (PLoS)
- Published
- 2009-07-31
- Volume
- 5
- Issue
- 7
- Pages
- e1000450
- ISSN
- 1553-734X (ISSN-L)
- 1553-7358
- OpenAlex
- W2075897300
- Cited by
- 185
- References
- 9
- FWCI
- 4.80
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.